{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:55Z","timestamp":1792790515086,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie - Linfomi e Mieloma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022ZKKWLW"],"award-info":[{"award-number":["2022ZKKWLW"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR"],"award-info":[{"award-number":["PNRR"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02362532"],"award-info":[{"award-number":["RF-2016-02362532"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"\u201cSociet\u00e0 Italiana di Medicina Interna \u2013 SIMI\u201d 2023 Research Award","id":[{"id":"https:\/\/ror.org\/0017x6m71","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2018-22059"],"award-info":[{"award-number":["IG2018-22059"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is a plasma cell (PC) disorder characterized by skeletal involvement at the time of diagnosis. Recently, cell-free DNA (cfDNA) has been proven to recapitulate the heterogeneity of bone marrow (BM) disease. Our aim was to evaluate the prognostic role of cfDNA at diagnosis according to disease distribution, and to investigate the role of the MM microenvironment inflammatory state in supplying the release of cfDNA. A total of 162 newly diagnosed MM patients were screened using 18F-FDG PET\/CT and assessed by ultra low-pass whole genome sequencing (ULP-WGS). High cfDNA tumor fraction (ctDNA) levels were correlated with different tumor mass markers, and patients with high ctDNA levels at diagnosis were more likely to present with metabolically active paraskeletal (PS) and extramedullary (EM) lesions. Moreover, we demonstrated that microenvironment cancer-associated fibroblast (CAFs)-mediated inflammation might correlate with high ctDNA levels. Indeed, a high cfDNA TF level at diagnosis predicted a poorer prognosis, independent of R-ISS III and 1q amplification; the inclusion of &gt;12% ctDNA in the current R-ISS risk score enables a better identification of high-risk patients. ctDNA can be a reliable and less invasive marker for disease characterization, and can refine patient risk.<\/jats:p>","DOI":"10.1038\/s41408-024-01185-6","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T03:46:35Z","timestamp":1732765595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-8707","authenticated-orcid":false,"given":"Marina","family":"Martello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-6955","authenticated-orcid":false,"given":"Vincenza","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Mazzocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0174-2052","authenticated-orcid":false,"given":"Davide","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Taurisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajsi","family":"Kanapari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0753-1248","authenticated-orcid":false,"given":"Andrea","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Vigliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"Pistis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Desantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marzocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pantani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-3227","authenticated-orcid":false,"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4948-4785","authenticated-orcid":false,"given":"Carolina","family":"Terragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"1185_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-16-0184","volume":"22","author":"P Neri","year":"2016","unstructured":"Neri P, Bahlis NJ, Lonial S. New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma. Clin Cancer Res. 2016;22:5959\u201365.","journal-title":"Clin Cancer Res"},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/OP.21.00032","volume":"17","author":"M Mohan","year":"2021","unstructured":"Mohan M, Hari P, Dhakal B. Immunotherapy in multiple myeloma-time for a second major paradigm shift. JCO Oncol Pract. 2021;17:405\u201313.","journal-title":"JCO Oncol Pract"},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fonc.2019.00699","volume":"9","author":"A Romano","year":"2019","unstructured":"Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives. Front Oncol. 2019;9:699.","journal-title":"Front Oncol"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059\u201368.","journal-title":"Blood"},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","volume":"21","author":"E Zamagni","year":"2015","unstructured":"Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, et al. PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21:4384\u201390.","journal-title":"Clin Cancer Res"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mri.2020.10.005","volume":"75","author":"A Latifoltojar","year":"2021","unstructured":"Latifoltojar A, Boyd K, Riddell A, Kaiser M, Messiou C. Characterizing spatial heterogeneity of multiple myeloma in high resolution by whole-body magnetic resonance imaging: towards macro-phenotype driven patient management. Magn Reson Imaging. 2021;75:60\u201364.","journal-title":"Magn Reson Imaging"},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Rasche","year":"2018","unstructured":"Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132:59\u201366.","journal-title":"Blood"},{"key":"1185_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"},{"key":"1185_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32145-y","volume":"13","author":"L Rasche","year":"2022","unstructured":"Rasche L, Schinke C, Maura F, Bauer MA, Ashby C, Deshpande S, et al. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022;13:4517.","journal-title":"Nat Commun"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1378\u201390.","journal-title":"Lancet Oncol"},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/hematology.2021000230","volume":"2021","author":"AJ Yee","year":"2021","unstructured":"Yee AJ, Raje N. Minimal residual disease in multiple myeloma: why, when, where. Hematol Am Soc Hematol Educ Program. 2021;2021:37\u201345.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1185_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01543-7","volume":"21","author":"SN Lone","year":"2022","unstructured":"Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21:79.","journal-title":"Mol Cancer"},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, More S, Corradini P, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:3120\u201331.","journal-title":"J Clin Oncol"},{"key":"1185_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0139-7","volume":"8","author":"S Faict","year":"2018","unstructured":"Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8:105.","journal-title":"Blood Cancer J"},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","volume":"129","author":"S Manier","year":"2017","unstructured":"Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129:2429\u201336.","journal-title":"Blood"},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754\u201365.","journal-title":"N Engl J Med"},{"key":"1185_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01710-w","volume":"22","author":"P Stejskal","year":"2023","unstructured":"Stejskal P, Goodarzi H, Srovnal J, Hajduch M, van \u2018t Veer LJ, Magbanua MJM. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023;22:15.","journal-title":"Mol Cancer"},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","volume":"36","author":"JM Waldschmidt","year":"2022","unstructured":"Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, et al. Cell-free DNA for the detection of emerging treatment failure in relapsed\/ refractory multiple myeloma. Leukemia. 2022;36:1078\u201387.","journal-title":"Leukemia"},{"key":"1185_CR21","first-page":"26","volume":"10","author":"D Thakral","year":"2020","unstructured":"Thakral D, Das N, Basnal A, Gupta R. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet? Am J Blood Res. 2020;10:26\u201345.","journal-title":"Am J Blood Res"},{"key":"1185_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04001-5","volume":"9","author":"S Manier","year":"2018","unstructured":"Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun. 2018;9:1691.","journal-title":"Nat Commun"},{"key":"1185_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74288-2","volume":"10","author":"M Korabecna","year":"2020","unstructured":"Korabecna M, Zinkova A, Brynychova I, Chylikova B, Prikryl P, Sedova L, et al. Cell-free DNA in plasma as an essential immune system regulator. Sci Rep. 2020;10:17478.","journal-title":"Sci Rep"},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","volume":"36","author":"EM Lauer","year":"2022","unstructured":"Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36:2151\u201364.","journal-title":"Leukemia"},{"key":"1185_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0111-6","volume":"8","author":"E Bohers","year":"2018","unstructured":"Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8:74.","journal-title":"Blood Cancer J"},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047\u20138.","journal-title":"Bioinformatics"},{"key":"1185_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinss on","year":"2017","unstructured":"Adalsteinss on VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun"},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.csbj.2022.06.062","volume":"20","author":"G Mazzocchetti","year":"2022","unstructured":"Mazzocchetti G, Poletti A, Solli V, Borsi E, Martello M, Vigliotta I, et al. BoBafit: a copy number clustering tool designed to refit and recalibrate the baseline region of tumors\u2019 profiles. Comput Struct Biotechnol J. 2022;20:3718\u201328.","journal-title":"Comput Struct Biotechnol J"},{"key":"1185_CR31","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537\u201347.","journal-title":"Nat Biotechnol"},{"key":"1185_CR32","doi-asserted-by":"crossref","unstructured":"Grabuschnig S, Bronkhorst AJ, Holdenrieder S, Rosales Rodriguez I, Schliep KP, Schwendenwein D, et al. Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. Int J Mol Sci. 2020;21:8062.","DOI":"10.3390\/ijms21218062"},{"key":"1185_CR33","doi-asserted-by":"crossref","unstructured":"Kubicki T, Derman BA, Dytfeld D, Jakubowiak AJ. Measurable residual disease in peripheral blood in myeloma: dream or reality. Curr Opin Oncol. 2023;35:574\u201380","DOI":"10.1097\/CCO.0000000000000987"},{"key":"1185_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101142","volume":"33","author":"JR Chapman","year":"2020","unstructured":"Chapman JR, Thoren KL. Tracking of low disease burden in multiple myeloma: using mass spectrometry assays in peripheral blood. Best Pr Res Clin Haematol. 2020;33:101142.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1185_CR35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114\u201324.","journal-title":"Nat Med"},{"key":"1185_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13402-021-00590-4","volume":"44","author":"C Kuang","year":"2021","unstructured":"Kuang C, Zhu Y, Guan Y, Xia J, Ouyang J, Liu G, et al. COX2 confers bone marrow stromal cells to promoting TNF\u03b1\/TNFR1\u03b2-mediated myeloma cell growth and adhesion. Cell Oncol. 2021;44:643\u201359.","journal-title":"Cell Oncol"},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322\u201332.","journal-title":"Exp Mol Med"},{"key":"1185_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"1185_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/path.5852","volume":"256","author":"I Saltarella","year":"2022","unstructured":"Saltarella I, Lamanuzzi A, Desantis V, Di Marzo L, Melaccio A, Curci P, et al. Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs. J Pathol. 2022;256:402\u201313.","journal-title":"J Pathol"},{"key":"1185_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hon.954","volume":"29","author":"MP Purdue","year":"2011","unstructured":"Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, et al. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol. 2011;29:42\u201346.","journal-title":"Hematol Oncol"},{"key":"1185_CR41","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","volume":"32","author":"S Xu","year":"2018","unstructured":"Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? Leukemia. 2018;32:1500\u201314.","journal-title":"Leukemia"},{"key":"1185_CR42","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022;139:3708\u201321.","journal-title":"Blood"},{"key":"1185_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00404-017-4547-x","volume":"296","author":"JX Pan","year":"2017","unstructured":"Pan JX, Qu F, Wang FF, Xu J, Mu LS, et al. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. Arch Gynecol Obstet. 2017;296:1145\u201352.","journal-title":"Arch Gynecol Obstet"},{"key":"1185_CR44","doi-asserted-by":"publisher","first-page":"29016","DOI":"10.18632\/oncotarget.5032","volume":"6","author":"MA Pavon","year":"2015","unstructured":"Pavon MA, Arroyo-Solera I, Tellez-Gabriel M, Leon X, Viros D, Lopez M, et al. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget. 2015;6:29016\u201333.","journal-title":"Oncotarget"},{"key":"1185_CR45","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-14-0847","volume":"20","author":"A Ferrucci","year":"2014","unstructured":"Ferrucci A, Moschetta M, Frassanito MA, Berardi S, Catacchio I, Ria R, et al. A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clin Cancer Res. 2014;20:5796\u2013807.","journal-title":"Clin Cancer Res"},{"key":"1185_CR46","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1172\/JCI123106","volume":"129","author":"JV McCann","year":"2019","unstructured":"McCann JV, Xiao L, Kim DJ, Khan OF, Kowalski PS, Anderson DG, et al. Endothelial miR-30c suppresses tumor growth via inhibition of TGF-beta-induced Serpine1. J Clin Invest. 2019;129:1654\u201370.","journal-title":"J Clin Invest"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01185-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01185-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:28:33Z","timestamp":1732771713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01185-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01185-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent for biological studies (Ethical Committee n. 167\/2019\/Sper\/AUOBo).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"208"}}